[1] [Expert consensus of the diagnosis and treatment measures for the Chinese elderly patients with type 2 diabetes (2018 Edition)], Zhonghua nei ke za zhi 57(9) (2018) 626-641.
[2] [Chinese guideline on healthy lifestyle to prevent cardiometabolic diseases], Zhonghua Yu Fang Yi Xue Za Zhi 54(3) (2020) 256-277.
[3] M.A. Abdul-Ghani, K. Williams, R.A. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes?, Diabetes care 30(6) (2007) 1544-1548.
[4] M. Manco, S. Panunzi, D.P. Macfarlane, A. Golay, O. Melander, T. Konrad, J.R. Petrie, G. Mingrone, One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study, Diabetes care 33(9) (2010) 2090-2097.
[5] M.A. Abdul-Ghani, M.P. Stern, V. Lyssenko, T. Tuomi, L. Groop, R.A. Defronzo, Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose, Diabetes care 33(3) (2010) 557-561.
[6] F. Guerrero-Romero, L.E. Simental-Mendía, M. González-Ortiz, E. Martínez-Abundis, M.G. Ramos-Zavala, S.O. Hernández-González, O. Jacques-Camarena, M. Rodríguez-Morán, The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp, J Clin Endocrinol Metab 95(7) (2010) 3347-3351.
[7] T. Du, G. Yuan, M. Zhang, X. Zhou, X. Sun, X. Yu, Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance, Cardiovasc Diabetol 13 (2014) 146.
[8] A.C.J. Vasques, F.S. Novaes, M.d.S. de Oliveira, J.R.M. Souza, A. Yamanaka, J.C. Pareja, M.A. Tambascia, M.J.A. Saad, B. Geloneze, TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study, Diabetes Res Clin Pract 93(3) (2011).
[9] L.E. Simental-Mendía, M. Rodríguez-Morán, F. Guerrero-Romero, The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects, Metab Syndr Relat Disord 6(4) (2008) 299-304.
[10] 2016 Chinese guidelines for the management of dyslipidemia in adults, Journal of geriatric cardiology : JGC 15(1) (2018).
[11] K. Thygesen, J.S. Alpert, A.S. Jaffe, B.R. Chaitman, J.J. Bax, D.A. Morrow, H.D. White, Fourth Universal Definition of Myocardial Infarction (2018), Circulation 138(20) (2018) e618-e651.
[12] K.A. Hicks, J.E. Tcheng, B. Bozkurt, B.R. Chaitman, D.E. Cutlip, A. Farb, G.C. Fonarow, J.P. Jacobs, M.R. Jaff, J.H. Lichtman, M.C. Limacher, K.W. Mahaffey, R. Mehran, S.E. Nissen, E.E. Smith, S.L. Targum, 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards), J Am Coll Cardiol 66(4) (2015) 403-469.
[13] F. de Vegt, J.M. Dekker, H.G. Ruhé, C.D. Stehouwer, G. Nijpels, L.M. Bouter, R.J. Heine, Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study, Diabetologia 42(8) (1999) 926-931.
[14] Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?, Diabetes care 26(3) (2003) 688-696.
[15] J.B. Meigs, D.M. Nathan, R.B. D'Agostino, P.W.F. Wilson, Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study, Diabetes care 25(10) (2002) 1845-1850.
[16] J.H. Fuller, M.J. Shipley, G. Rose, R.J. Jarrett, H. Keen, Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study, Lancet 1(8183) (1980) 1373-1376.
[17] M. Laakso, Hyperglycemia and cardiovascular disease in type 2 diabetes, Diabetes 48(5) (1999) 937-942.
[18] M.A. Abdul-Ghani, V. Lyssenko, T. Tuomi, R.A. DeFronzo, L. Groop, Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study, Diabetes care 32(2) (2009) 281-6.
[19] L.X. Cubeddu, I.S. Hoffmann, One-hour postload plasma glucose levels, a predictor of additional risk for diabetes: prevalence, mechanisms, and associated cardiovascular and metabolic risk factors in Hispanics, Metab Syndr Relat Disord 8(5) (2010) 395-402.
[20] A. Sciacqua, R. Maio, S. Miceli, A. Pascale, G. Carullo, N. Grillo, F. Arturi, G. Sesti, F. Perticone, Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension, PLoS ONE 7(9) (2012) e44470.
[21] M.A. Marini, E. Succurro, S. Frontoni, S. Mastroianni, F. Arturi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels, Diabetes care 35(4) (2012) 868-872.
[22] F. Andreozzi, G.C. Mannino, M. Perticone, F. Perticone, G. Sesti, Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile, Atherosclerosis 256 (2017) 15-20.
[23] C. Bianchi, R. Miccoli, M. Trombetta, F. Giorgino, S. Frontoni, E. Faloia, G. Marchesini, M.A. Dolci, F. Cavalot, G. Cavallo, F. Leonetti, R.C. Bonadonna, S. Del Prato, G. Investigators, Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired beta-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study, J Clin Endocrinol Metab 98(5) (2013) 2100-5.
[24] M.A. Marini, T.V. Fiorentino, F. Andreozzi, G.C. Mannino, M. Perticone, A. Sciacqua, F. Perticone, G. Sesti, Elevated 1-h post-challenge plasma glucose levels in subjects with normal glucose tolerance or impaired glucose tolerance are associated with whole blood viscosity, Acta Diabetol 54(8) (2017) 775-784.
[25] A. Sciacqua, S. Miceli, G. Carullo, L. Greco, E. Succurro, F. Arturi, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients, Diabetes Care 34(6) (2011) 1406-1411.
[26] E. Succurro, M.A. Marini, F. Arturi, A. Grembiale, M. Lugarà, F. Andreozzi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis, Atherosclerosis 207(1) (2009) 245-249.
[27] A. Di Pino, F. Urbano, R. Scicali, S. Di Mauro, A. Filippello, A. Scamporrino, S. Piro, F. Purrello, A.M. Rabuazzo, 1 h Postload Glycemia Is Associated with Low Endogenous Secretory Receptor for Advanced Glycation End Product Levels and Early Markers of Cardiovascular Disease, Cells 8(8) (2019).
[28] E. Selvin, M.W. Steffes, H. Zhu, K. Matsushita, L. Wagenknecht, J. Pankow, J. Coresh, F.L. Brancati, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med 362(9) (2010) 800-811.
[29] J. Malmstedt, L. Kärvestedt, J. Swedenborg, K. Brismar, The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study, Cardiovasc Diabetol 14 (2015) 93.
[30] K.E. Bornfeldt, I. Tabas, Insulin resistance, hyperglycemia, and atherosclerosis, Cell Metab 14(5) (2011) 575-585.
[31] C.C.L. Wang, I. Gurevich, B. Draznin, Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways, Diabetes 52(10) (2003) 2562-2569.
[32] G. Wu, C.J. Meininger, Nitric oxide and vascular insulin resistance, Biofactors 35(1) (2009) 21-27.
[33] K.B. Gast, N. Tjeerdema, T. Stijnen, J.W.A. Smit, O.M. Dekkers, Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis, PLoS ONE 7(12) (2012) e52036.
[34] G. Howard, D.H. O'Leary, D. Zaccaro, S. Haffner, M. Rewers, R. Hamman, J.V. Selby, M.F. Saad, P. Savage, R. Bergman, Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators, Circulation 93(10) (1996) 1809-1817.
[35] I.J. Goldberg, C.M. Trent, P.C. Schulze, Lipid metabolism and toxicity in the heart, Cell Metab 15(6) (2012) 805-812.
[36] D. Feuvray, J.A. Idell-Wenger, J.R. Neely, Effects of ischemia on rat myocardial function and metabolism in diabetes, Circ Res 44(3) (1979) 322-329.
[37] C. Bianchi, R. Miccoli, M. Trombetta, F. Giorgino, S. Frontoni, E. Faloia, G. Marchesini, M.A. Dolci, F. Cavalot, G. Cavallo, F. Leonetti, R.C. Bonadonna, S. Del Prato, Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study, J Clin Endocrinol Metab 98(5) (2013) 2100-2105.
[38] M.A. Abdul-Ghani, V. Lyssenko, T. Tuomi, R.A. DeFronzo, L. Groop, Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study, Diabetes Care 32(2) (2009) 281-286.
*[1] PMID: 30180447 DOI: 10.3760/cma.j.issn.0578-1426.2018.09.004
*[2] PMID: 32100977 DOI: 10.3760/cma.j.issn.0253-9624.2020.03.006
*[10] PMID: 29434622 DOI: 10.11909/j.issn.1671-5411.2018.01.011
*[27] PMID:31426413 DOI: 10.33901cells8080910